Joel Greenblatt's HAE Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 18,814 shares of Haemonetics Corporation (HAE) worth $1.51 M, representing 0.01% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in HAE, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2018, adding 129,218 shares. Largest reduction occurred in Q2 2018, reducing 98,869 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Haemonetics Corporation (HAE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Haemonetics Corporation (HAE) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -4,114 | Reduce 17.94% | 18,814 | $80.15 |
| Q3 2025 | +91 | Add 0.40% | 22,928 | $48.74 |
| Q2 2025 | +18,158 | Add 388.07% | 22,837 | $74.61 |
| Q1 2025 | -235 | Reduce 4.78% | 4,679 | $63.55 |
| Q3 2024 | -4 | Reduce 0.08% | 4,914 | $80.38 |
| Q2 2024 | -3,694 | Reduce 42.89% | 4,918 | $82.73 |
| Q1 2024 | -15,318 | Reduce 64.01% | 8,612 | $85.35 |
| Q4 2023 | -2,588 | Reduce 9.76% | 23,930 | $85.51 |
| Q3 2023 | +5,352 | Add 25.29% | 26,518 | $89.58 |
| Q2 2023 | +13,668 | Add 182.29% | 21,166 | $85.14 |
| Q1 2023 | -4,187 | Reduce 35.83% | 7,498 | $82.75 |
| Q4 2022 | +6,542 | Add 127.20% | 11,685 | $78.65 |
| Q3 2022 | -1 | Reduce 0.02% | 5,143 | $74.08 |
| Q2 2022 | +5,144 | New Buy | 5,144 | $65.12 |
| Q1 2022 | -6,453 | Sold Out | 0 | $0.00 |
| Q4 2021 | -341 | Reduce 5.02% | 6,453 | $53.00 |
| Q3 2021 | +6,794 | New Buy | 6,794 | $70.65 |
| Q3 2020 | -6,684 | Sold Out | 0 | $0.00 |
| Q2 2020 | -14,582 | Reduce 68.57% | 6,684 | $89.62 |
| Q1 2020 | +16,377 | Add 334.98% | 21,266 | $99.64 |
| Q4 2019 | +4,889 | New Buy | 4,889 | $114.95 |
| Q2 2019 | -18,653 | Sold Out | 0 | $0.00 |
| Q1 2019 | -18,111 | Reduce 49.26% | 18,653 | $87.49 |
| Q4 2018 | -8,903 | Reduce 19.50% | 36,764 | $100.04 |
| Q3 2018 | -9,805 | Reduce 17.68% | 45,667 | $114.59 |
| Q2 2018 | -98,869 | Reduce 64.06% | 55,472 | $89.68 |
| Q1 2018 | +129,218 | Add 514.34% | 154,341 | $73.16 |
| Q4 2017 | -30,438 | Reduce 54.78% | 25,123 | $58.07 |
| Q3 2017 | +18,088 | Add 48.27% | 55,561 | $44.87 |
| Q2 2017 | +21,665 | Add 137.05% | 37,473 | $39.50 |
| Q1 2017 | +15,808 | New Buy | 15,808 | $40.55 |
| Q3 2016 | -39,575 | Sold Out | 0 | $0.00 |
| Q2 2016 | +39,575 | New Buy | 39,575 | $28.98 |
| Q3 2015 | -35,271 | Sold Out | 0 | $0.00 |
| Q2 2015 | +27,761 | Add 369.65% | 35,271 | $41.37 |
| Q1 2015 | +7,510 | New Buy | 7,510 | $44.87 |
| Q4 2014 | -29,531 | Sold Out | 0 | $0.00 |
| Q3 2014 | -9,059 | Reduce 23.47% | 29,531 | $34.91 |
| Q2 2014 | -4,219 | Reduce 9.86% | 38,590 | $35.27 |
| Q1 2014 | +42,809 | New Buy | 42,809 | $32.59 |
Joel Greenblatt's Haemonetics Corporation Investment FAQs
Joel Greenblatt first purchased Haemonetics Corporation (HAE) in Q1 2014, acquiring 42,809 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Haemonetics Corporation (HAE) for 41 quarters since Q1 2014.
Joel Greenblatt's largest addition to Haemonetics Corporation (HAE) was in Q1 2018, adding 154,341 shares worth $11.29 M.
According to the latest 13F filing for Q4 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 18,814 shares of Haemonetics Corporation (HAE), valued at approximately $1.51 M.
As of the Q4 2025 filing, Haemonetics Corporation (HAE) represents approximately 0.01% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Haemonetics Corporation (HAE) was 154,341 shares, as reported at the end of Q1 2018.